Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,816.89
(
-0.11%
)
US TECH 100
24,461.60
(
0.22%
)
Dow Jones
47,916.57
(
-0.56%
)
Brent Oil
92.41
(
-2.17%
)
Bitcoin
72,932.98
(
1.59%
)
News Focus
News Focus
Post# of 257378
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122860
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 123665

Wednesday, 07/20/2011 10:37:50 PM

Wednesday, July 20, 2011 10:37:50 PM

Post# of 257378
I cannot concur with your characterization of the ICGN buyout as pathetic insofar as the buyout price of $6 is a 150% premium to ICGN’s unaffected share price. This is one of the highest premiums in any recent biotech acquisition (#msg-65401590).

Assuming the share price must go up when a company in play gets acquired is just as silly as assuming the share price must go up when a company gets FDA approval. People on this board are too smart for that, IMO.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today